Prisms, Vision Therapy Reduce AACE
Retrospective cohort shows 79% of patients improved without surgery, with measurable gains in divergence and reduced esodeviation
By
Julie Greenbaum
March 5, 2026
Clinical Scorecard: Prisms, Vision Therapy Reduce AACE
At a Glance
Category Detail
Condition Acute Acquired Comitant Esotropia (AACE) Key Mechanisms Non-surgical management using prisms and vision therapy to improve divergence and reduce esodeviation. Target Population Patients with non-accommodative, non-neurologic AACE, primarily Type II. Care Setting Tertiary eye care center
Key Highlights
79% of patients showed improvement with prisms and vision therapy. Median distance esodeviation decreased by about 7 prism diopters post-therapy. Divergence amplitudes improved by approximately 7 PD at distance and 8 PD at near. 36% achieved stable binocular single vision with vision therapy alone. No patients reported diplopia after therapy. Guideline-Based Recommendations
Diagnosis
Evaluate patients for non-accommodative, non-neurologic AACE. Exclude patients with accommodative, decompensated, neurologic, cyclic, or secondary forms of AACE. Management
Prescribe Fresnel prisms for constant diplopia, focusing on the smallest effective magnitude. Implement divergence-focused vision therapy, including in-office and home-based exercises. Monitoring & Follow-up
Assess changes in negative fusional vergence and esodeviation before and after therapy. Risks
Potential for residual esodeviation in larger deviations. Limitations include retrospective design and lack of control group. Patient & Prescribing Data
34 patients evaluated, 14 included in analysis with Type II AACE.
Vision therapy alone may suffice for esodeviation of 20 PD or less; larger deviations often require combined therapy.
Clinical Best Practices
Utilize a combination of prisms and vision therapy for effective management of AACE. Encourage regular follow-up and maintenance exercises post-therapy. Related Resources & Content
